EVMed

EVMed Group Biotechnology is an innovative life sciences company specialized in the research, development, and manufacturing of extracellular vesicle (EV) and exosome-based technologies. Founded in 2015 and headquartered in Suzhou, China, the company provides an integrated ecosystem for exosome isolation, engineering, and clinical translation through its proprietary platforms, including ExoCell™ for engineered EV production and ExoPure™ for high-efficiency purification. EVMed integrates advanced R&D with GMP-certified manufacturing facilities in Shaoxing and Suzhou to address unmet needs in oncology, regenerative medicine, and vaccines. In 2024, the company expanded its international footprint by establishing APEX in Oman, facilitating global access to its standardized exosome-based therapeutic and diagnostic solutions. The company also operates the Umibio brand, which provides specialized exosome research tools and reagents to the global scientific community.